Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — JP Morgan Healthcare Conference 2016
32 slides from Angiodynamics's conference presentation, Jan 13, 2016
Slide 1: JP Morgan Healthcare Conference
>) angiodynamics JP Morgan Healthcare Conference Joseph M. DeVivo, President and CEO January 13, 2016 ADVANCING CARE. REDUCING COMPLICATIONS. MINIMIZING COSTS.
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward Looking Statements This release contains forwarcHooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics expected future financial position, results of operations, cash fl
Slide 3: Profile of AngioDynamics
Profile of AngioD Global, leading provider of innovative, image-guided, minimally invasive solutions. Fi hises: Founded: 1998 Employee Base: Peri a Vacwular IPO: May 2004 1,300 employees Vencaler ecoes ANGO (NASDAQ) 7 operating locations Oncology/Surgery Global Footprint: 210+ global sales team in U
Slide 4: IR Heritage Drives Future Growth
IR Heritage Drives Future Growth In 1990, AngioDynamics began manufacturing diagnostic catheters to serve the emerging practice of the interventional radiologist. Every development since then has resulted from the company’s commitment to serving interventional radiologists and their ability to offer
Slide 5: Our Strategic Foundation
Our Strategic Foundation Improve patient outcomes while lowering overall costs within the healthcare system and maximizing shareholder value 3 Transform through operational excellence 5 >) angiodynamics
Slide 6: Economic and Quality Measures
Economic and Quality Measures Clinical Value Economic Value * Global prevalence * Severe disability * High mortality * Growing incidence * Complex management + Substantial healthcare costs + Absence of therapy -| * Limitations in efficacy * High complication risk * Difficulty with device use + Patie
Slide 7: Improving Patient Outcomes by Investing in Growth Drivers
IMPROVING PATIENT OUTCOMES BY INVESTING IN GROWTH DRIVERS 7 i>) angiodynamics
Slide 8: Peripheral Vascular Overview
Peripheral Vascular Overview Thrombus Venous Fluid Management Insufficiency Management em i < } ey ass . \ rs, Vyas : Wn, . Angiographic Drainage Catheters a vP( FY2015 Revenue: $193 million >) angiodynamics
Slide 9: Clinical Unmet Need: VTE
Clinical Unmet Need: VTE VENOUS THROMBOEMBOLISM (VTE) INCIDENCE Overall ~1 Million VTE Events per year in U.S. Additional: Overall 300,000 VTE Deaths per year in U.S. - #3 cause Annual Incidence 1,000,000 Heart 5 800,000 5 600,000 concen a 400,000 8 VIE 296,000 © 200,000 | o TOTAL copp [J 138,000 DV
Slide 10: The Thrombus Management Solution
The Thrombus Management Solution A COMPREHENSIVE SOLUTION FOR VENOUS THROMBOEMBOLISM AC Designed for the removal of soft, fresh thrombi or emboli, AngioVac venous drainage system includes the Venous Drainage Cannula and the Extracorporeal Circuit Comprehensive line of catheter / directed thrombolysi
Slide 11: Vascular Access Overview
Vascular Access Overview PICC Lines a Ports Dialysis Ss 2 ~ —. ee FY2015 Revenue: $108 million >) angiodynamics
Slide 12: Clinical Need: Addressable PICC Complication
Clinical Need: Addressable PICC Complication AVG. $450M —— 6x —> $2.65B AVG. RATE TREATMENT COST Upper Deep Veii $15,9731 -7.8%4 2.7M Pics us Placed Occlusions 25%?** $123.77 Annually Catheter-Related Bloodstream Infections: 0.4-0.8 per 1,000 $16,550? catheter days* OR 2.4%°> PICC Line Market Cost t
Slide 13: The BIOFLO Solution
The BIOFLO Solution A REVOLUTIONARY PICC TECHNOLOGY Minimizes complications associated w/ heparin Reduces risks associated w/ bacterial resistance ro} Present throughout 13 UNLIKE OTHER TECHNOLOGIES THAT ARE SUPERFICIAL AND/OR TRANSIENT, THE BIOFLO MATERIAL IS DESIGNED TO BE PRESENT THROUGHOUT THE C
Slide 14: Performance in Clinical Evaluation
Performance in Clinical Evalu FACILITY NAME NUMBER OF PICCs PLACED DVT REDUCTION Academic Medical Center 1,254 85% Community Hospital 533 25% Community Hospital 1,212 36% Hospital Group 252 79% MORE THAN International Hospital 60 46% 8,000 BIOFLO Health System 3,891 32% PICCs HAVE BEEN Academic Medi
Slide 15: Opportunity: BioFlo for Contracted Business
Opportunity: BioFlo for Contracted Business The Market AngioDynamics 5,686 Registered Acute O- 4,872 ~30% Care Hospitals Hospitals 5,441 Purchasing PICCS 512 Contracted pa Care Hospitals under a GPO Purchasing PICCs 90% Agreement GPO Contract History # of Hospitals that ANGO can officially sell PICC
Slide 16: Opportunity: BioFlo Midline
ity: BioFlo Midline NEW BIOFLO MARKET OPPORTUNITIES Midline product is drawing not only from the current PICC market, but also from the peripheral IV market CLINICAL ADVANTAGES 1. Ease of insertion for the clinician compared to other competitive devices 2. Consistently, effectively draws blood over
Slide 17: Opportunity: Tip Location Services
Opportunity: Tip Location Services Tip location, coupled with our innovative BioFlo Technology, will improve our competitive position in the PICC market v March 6, 2014: Acquired regulatory control over Celerity platform and rights to next generation technology v Mid-summer 2014: U.S. Clearance v Wi
Slide 18: Oncology / Surgery Overview
Oncology / Surgery Overview Non-Thermal Microwave Radiofrequency Surgical Ablation Ablation Ablation Resection FY2015 Revenue: $52 million 18 >) angiodynamics
Slide 19: Global Cancer Incidence
Global Cancer Incidence GLOBAL STATISTICS Cancer is the leading cause of death worldwidet 14 million new cases of cancer each year* 8.2 million cancer-related deaths in 2012+ and has not changed in over 50 years? Surgical Ablation Radiotherapy chemotherapy Palliative Treatment Most Common Causes of
Slide 20: AngioDynamics Leadership in Surgical Ablation
namics Leadership in Surgical Ablation AngioDynamics offers a full complement of tissue ablation products that provide clinicians maximum choice in treating patients. THERMAL { NON-THERMAL N StarBurst QA renornite seheeelienetts > micowae one 20 ® angiodynamics
Slide 21: The NanoKnife Solution
The NanoKnife Solution A REVOLUTIONARY SURGICAL TECHNOLOGY A new treatment modality for locally advanced pancreatic and hepatic tumors [o) iNOL fo} z * Series of short, low energy direct current electrical pulses * Does not rely on heat to ablate tissue * Creates defects (pores) in cell membranes *
Slide 22: Building Clinical Evidence for NanoKnife
Building Clinical Evidence for NanoKnife Mounting Clinical Data More than 150 peer reviewed articles published ANNALS OF SURGERY 2 i>) angiodynamics
Slide 23: Opportunity: Asia-Pacific
Opportunity: Asia-Pacific China = —Q) Japan Annual Cancer Annual Cancer polity Mortality: 9.8 million: 1.9 million? NanoKnife under review: —C) Taiwan Thailand Singapore Malaysia 4. hntto://www.who int/cancer/country-profiles/chn_en.pdf?ua=1. . . yg 2 Mip/Lannuuteint/cances/coutnesofles/im enpdrs=h
Slide 24: i>) angiodynamics
i>) angiodynamics
Slide 25: Strong Product Development Pipeline
Strong Product Development Pipeline* Inflation Device Drainage Line Extension AngioVac Line Extension Non-Vascular Introducer PainFree Laser Procedure New Thrombus Management Product Fluid Management Line Extension Celerity Navigation BioHo Port Line Extension BioHo PICC Line Extension FireFly Tip L
Slide 26: Transform Through Operational Excellence
TRANSFORM THROUGH OPERATIONAL EXCELLENCE i>) angiodynamics
Slide 27: Operational Improvements Plan and Impact
Operational Imp ts Plan and Impact Phase 1 - COMPLETE Phase 2 - EXECUTING Phase 3 - PLANNING Implement near-term Site consolidation: Global distribution strategy product family /_- Queensbury repurposed Assess global manufacturing Game SLeeuion/ ale rate as Distribution Center for footprint _ Grrain
Slide 28: Q2 Summary Financial Performance
28 Q2 Summary Fina cial Performance pouieee ere Net sales $89.2 $92.1 -3% -1%() GAAP Earnings per share (EPS) $(0.01) $0.04 -127% -108% Adjusted EPS® $0.14 $0.17 -19% -15% Free Cash Flow $9.2 $(4.6) - - AngioDynamics 1ECEMBER 3, 2015 BY BRAD PERRIELL FDA lifts final warning letters for AngioDyt of w
Slide 29: Summary Financial Performance
Summary Financial Performance Three months ended Nov 30, 2015 Six months ended Nov 30, 2015, ee alates Sales YoY Growth Sales YoY Growth ww $89.2 i 3% $172.9 -4% wwe $90.2 2% $174.9 3% w § sit % $2 1% VA $25.0 -11% $49.7 9% o/s $12.4 9% $23.7 9% ‘uU® CS si4 i HS~C~S soa Int'l $478 6% $32.5 -12% Int
Slide 30: Balance Sheet and Cash Flow
Balance Sheet and Cash Flow $ in millions Nov30, 2015 May 31, 2015 Cash & investments $20.6 $20.1 Net working capital $91.5 $90.3 Totalassets $760.4 $773.6 Totaldebt $133.9 $137.7 Total stockholder’s equity $547.6 $545.0 on milli 3 months ended 3 months ended $ in millions, except per share amounts
Slide 31: $ in millions, except per bison Throomonths sixmonthsended _Sixmonths ended
34 $ in millions, except per bison Throomonths sixmonthsended _Sixmonths ended share amounts Nov 30,2015 Nov 30,2014 Nov30, 2015 Nov30, 2014 Sales $89.2 $92.1 $172.9 $179.5 Gross margins 51.4% 51.7% 51.5% 52.1% Operating expenses $35.8 $36.1 $71.0 $71.2 Operating income $10.0 $11.6 $18.0 $22.3 Opera
Slide 32: AngioDynamics Transformation
ynamics Transformation Investor Profile Fiscal Guidance* * Major acquisitions - Navilyst (2012), $ in millions, except Vortex Medical (2012), Microsulis (2013) per share amounts Q3 Full-Year * Disruptive technology in PV, VA, and 0/S Sales $84-$87 $353-$359 markets with strong product pipeline Adjus